R'Biz - brought to you by James A. Bacon
Featured Post

Management & Strategy

Betting on Biologics

Englishman Geoffrey Allan is betting the future of the company he founded, Richmond-based Insmed, Inc., on the proposition that the U.S. Congress will reform patent laws preventing competition in a class of drugs, biologics, created by the biotech industry. Insmed is best known for IPLEX, a drug used in the treatment of certain “orphan” diseases affecting fewer than 200,000 people, but it is investing heavily as well in creating “follow-on biologics” -- generic versions --- of blockbuster drugs accounting for $10 billion in sales at today’s prices.

In an interview in the March/April issue of The American magazine, Allan outlines his bold strategy. Due to a loophole in the 1984 law overhauling the regulation of drugs in the United States, a class of drugs invented by the then-emerging biotech industry, known as biologics, was exempted from the 20-year limits on patent protection. When patent protections expire, competitors move into the market with cheaper generics, saving U.S. consumers untold billions of dollars. But the patent shield for biologics never ends.

 

“Biologic drugs now account for about $40 billion in U.S. sales,” says Allan. “Basically, there is no way that a generic manufacturer can come in when the patents have expired to copy these drugs and bring them to the market at a cheaper price. Consequently, these drugs cost the healthcare system a huge amount of money, and it has created a monopoly for the large biotechnology companies.”


Read More...
Posted by James A. Bacon on 5/13/2008 9:00:00 AM   |   0 comments
Race Season Strip - Race Season Strip08